Just incase people wanted further clarification that we should...

Just incase people wanted further clarification that we should be expecting preclinical breast cancer FTO results...

A highlighted section from the interum report:


Now, compare the table from the interum results to the table from the full results. Please, note the * at the bottom of the final results table.
Interum Table:


Final Table:


Multiple studies have shown that MCF-7 breast cancer cells overexpress FTO (1,2).
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437932/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452952/

In my opinion, this is undeniable evidence that the MCF-7 breast cancer cell lines were put into the study after the interum results to measure the FTO effect of bisantrene. We will receive data regarding the FTO effect of bisantrene in the MCF-7 breast cancer cell lines. In my opinion, the data will be positive and will provide the very first RAC-generated indication that bisantrenes mechanism of increased efficacy is a result of FTO inhibition in MCF-7 breast cancer cells resistant to other treatments.

When? Soon.

All IMO - DYOR.